- Home
- BETA vs PRAX Comparison
BETA vs PRAX Comparison
Compare BETA & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BETA | PRAX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 7.2B |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BETA | PRAX |
|---|---|---|
| Price | $28.02 | $277.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $39.29 | ★ $373.79 |
| AVG Volume (30 Days) | ★ 789.1K | 580.2K |
| Earning Date | 02-15-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,920,000.00 | $7,463,000.00 |
| Revenue This Year | $114.26 | N/A |
| Revenue Next Year | $7.10 | $12,467.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 88.32 | ★ 364.98 |
| 52 Week Low | $22.40 | $26.70 |
| 52 Week High | $39.50 | $317.72 |
Technical Indicators
Market Signals| Indicator | BETA | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 55.41 |
| Support Level | N/A | $268.78 |
| Resistance Level | N/A | $305.21 |
| Average True Range (ATR) | 0.00 | 15.32 |
| MACD | 0.00 | -3.91 |
| Stochastic Oscillator | 0.00 | 20.68 |
Price Performance
Historical ComparisonAbout BETA Beta Technologies Inc.
BETA Technologies Inc is an aerospace company manufacturing electric flight. It designs, manufactures and sells high-performance electric aircraft, advanced electric propulsion systems, charging systems and components. The company has one operating and reportable segment - Development and Manufacturing Electric Aircrafts. Its products include: Aircraft, Charge, Motor, Battery, and Flight Controls.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.